Double Bond Pharmaceutical receives Eurasian patent for the BeloGal® platform
Double Bond Pharmaceuticals patent application for organ-specific administration of hydrophilic cancer drug to the liver which forms the basis for the BeloGal® technology platform has been granted by the Eurasian Patent Organization (EAPO). Patent approval provides protection for the technology platform BeloGal® and products on the territory of 8 member states at least through 2035. "It is the company's second granted patent and we are very pleased that it concerns the geographically largest market. With the patent, we have achieved an important interim goal for the commercialization of